炎症小体、细胞焦亡与心肌缺血再灌注损伤中的细胞因子。
Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury.
机构信息
VCU Pauley Heart Center , Richmond, Virginia.
VCU Johnson Center for Critical Care and Pulmonary Research , Richmond, Virginia.
出版信息
Am J Physiol Heart Circ Physiol. 2018 Dec 1;315(6):H1553-H1568. doi: 10.1152/ajpheart.00158.2018. Epub 2018 Aug 31.
Abstract
Myocardial ischemia-reperfusion injury induces a sterile inflammatory response, leading to further injury that contributes to the final infarct size. Locally released danger-associated molecular patterns lead to priming and triggering of the NOD-like receptor protein 3 inflammasome and amplification of the inflammatory response and cell death by activation of caspase-1. We review strategies inhibiting priming, triggering, or caspase-1 activity or blockade of the inflammasome-related cytokines interleukin-1β and interleukin-18, focusing on the beneficial effects in experimental models of acute myocardial infarction in animals and the initial results of clinical translational research trials.
摘要
心肌缺血再灌注损伤会引起无菌性炎症反应，导致进一步的损伤，进而影响梗死面积。局部释放的危险相关分子模式会导致 NOD 样受体蛋白 3 炎性小体的激活和放大炎症反应和细胞死亡，从而导致 caspase-1 的激活。我们综述了抑制心肌缺血再灌注损伤的策略，包括抑制 NOD 样受体蛋白 3 炎性小体的激活和放大炎症反应和细胞死亡的 caspase-1 活性，以及阻断炎性小体相关细胞因子白细胞介素-1β和白细胞介素-18 的作用，重点介绍了在动物急性心肌梗死模型中的有益作用和临床转化研究试验的初步结果。
相似文献
1
Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury.
Am J Physiol Heart Circ Physiol. 2018 Dec 1;315(6):H1553-H1568. doi: 10.1152/ajpheart.00158.2018. Epub 2018 Aug 31.
2
Beta-Asarone Alleviates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammatory Response and NLRP3 Inflammasome Mediated Pyroptosis.
Biol Pharm Bull. 2020 Jul 1;43(7):1046-1051. doi: 10.1248/bpb.b19-00926. Epub 2020 Apr 22.
3
Cell-Specific Roles of NLRP3 Inflammasome in Myocardial Infarction.
J Cardiovasc Pharmacol. 2019 Sep;74(3):188-193. doi: 10.1097/FJC.0000000000000709.
4
Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury.
Circulation. 2011 Feb 15;123(6):594-604. doi: 10.1161/CIRCULATIONAHA.110.982777. Epub 2011 Jan 31.
5
NLRP3 Inflammasome in Acute Myocardial Infarction.
J Cardiovasc Pharmacol. 2019 Sep;74(3):175-187. doi: 10.1097/FJC.0000000000000717.
6
The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury.
Cardiovasc Res. 2013 Jul 1;99(1):164-74. doi: 10.1093/cvr/cvt091. Epub 2013 Apr 10.
7
Naoxintong attenuates Ischaemia/reperfusion Injury through inhibiting NLRP3 inflammasome activation.
J Cell Mol Med. 2017 Jan;21(1):4-12. doi: 10.1111/jcmm.12915. Epub 2016 Oct 26.
8
Lipopolysaccharide (LPS) Aggravates High Glucose- and Hypoxia/Reoxygenation-Induced Injury through Activating ROS-Dependent NLRP3 Inflammasome-Mediated Pyroptosis in H9C2 Cardiomyocytes.
J Diabetes Res. 2019 Feb 17;2019:8151836. doi: 10.1155/2019/8151836. eCollection 2019.
9
NLRP3 Inflammasome Activation-Mediated Pyroptosis Aggravates Myocardial Ischemia/Reperfusion Injury in Diabetic Rats.
Oxid Med Cell Longev. 2017;2017:9743280. doi: 10.1155/2017/9743280. Epub 2017 Sep 14.
10
The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse.
J Cardiovasc Pharmacol. 2019 Apr;73(4):215-222. doi: 10.1097/FJC.0000000000000658.
引用本文的文献
1
Sevoflurane Suppresses Cardiomyocyte Pyroptosis in Myocardial Ischemia via NLRP3 Inflammasome Signaling.
Anal Cell Pathol (Amst). 2025 Aug 24;2025:7119597. doi: 10.1155/ancp/7119597. eCollection 2025.
2
Innovative Nanotechnology and Molecular Probes for Real-time Monitoring and Therapeutic Modulation of Pyroptosis in Cancer and Inflammatory Diseases.
Cell Biochem Biophys. 2025 Sep 1. doi: 10.1007/s12013-025-01868-2.
3
Research progress on programmed cell death of cardiomyocytes in pressure-overload hypertrophic cardiomyopathy.
Apoptosis. 2025 Aug 14. doi: 10.1007/s10495-025-02146-5.
4
Ischemia-Reperfusion Injury in Free Flaps: Molecular Mechanisms and Protective Effects of Remote Ischemic Preconditioning.
J Cell Mol Med. 2025 Aug;29(15):e70739. doi: 10.1111/jcmm.70739.
5
High-intensity interval training improves mitochondrial function and attenuates cardiomyocytes damage in ischemia-reperfusion.
Int J Cardiol Heart Vasc. 2025 Jul 25;60:101756. doi: 10.1016/j.ijcha.2025.101756. eCollection 2025 Oct.
6
Nuclear Receptor ERRγ Protects Against Cardiac Ischemic Injury by Suppressing GBP5-Mediated Myocardial Inflammation.
FASEB J. 2025 Jul 31;39(14):e70819. doi: 10.1096/fj.202500763R.
7
Comprehensive bioinformatics analysis and experimental verification identify mitochondrial gene Dgat2 as a novel therapeutic biomarker for myocardial ischemia-reperfusion.
Front Endocrinol (Lausanne). 2025 May 29;16:1539646. doi: 10.3389/fendo.2025.1539646. eCollection 2025.
8
The Value of the Naples Prognostic Score and the Systemic Immune-Inflammation Index in Predicting Ischemia on Myocardial Perfusion Scintigraphy.
Diagnostics (Basel). 2025 May 29;15(11):1372. doi: 10.3390/diagnostics15111372.
9
Rutin Protects Myocardial Ischemia-Reperfusion Injury via the NF-κB/NLRP3/Pyroptosis Pathway.
ACS Omega. 2025 May 16;10(21):21777-21785. doi: 10.1021/acsomega.5c01408. eCollection 2025 Jun 3.
10
The protective effect of iron isomaltoside on myocardial ischemia-reperfusion injury via the suppression of KLF4/NF-κB signaling.
PLoS One. 2025 Jun 5;20(6):e0323247. doi: 10.1371/journal.pone.0323247. eCollection 2025.
本文引用的文献
1
Usefulness of Canakinumab to Improve Exercise Capacity in Patients With Long-Term Systolic Heart Failure and Elevated C-Reactive Protein.
Am J Cardiol. 2018 Oct 15;122(8):1366-1370. doi: 10.1016/j.amjcard.2018.07.002. Epub 2018 Jul 20.
2
Mitochondrial Membrane Permeability Inhibitors in Acute Myocardial Infarction: Still Awaiting Translation.
JACC Basic Transl Sci. 2016 Oct 31;1(6):524-535. doi: 10.1016/j.jacbts.2016.06.012. eCollection 2016 Oct.
3
Interleukin-1 Blockade in Acute Myocardial Infarction and Heart Failure: Getting Closer and Closer.
JACC Basic Transl Sci. 2017 Aug 28;2(4):431-433. doi: 10.1016/j.jacbts.2017.07.006. eCollection 2017 Aug.
4
The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure.
JACC Basic Transl Sci. 2017 Aug 28;2(4):418-430. doi: 10.1016/j.jacbts.2017.06.005. eCollection 2017 Aug.
5
Structural Insights of Benzenesulfonamide Analogues as NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization.
J Med Chem. 2018 Jun 28;61(12):5412-5423. doi: 10.1021/acs.jmedchem.8b00733. Epub 2018 Jun 18.
6
OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1530-E1539. doi: 10.1073/pnas.1716095115. Epub 2018 Jan 29.
7
Gasdermin D Flashes an Exit Signal for IL-1.
Immunity. 2018 Jan 16;48(1):1-3. doi: 10.1016/j.immuni.2018.01.003.
8
Autophagy limits activation of the inflammasomes.
Immunol Rev. 2018 Jan;281(1):62-73. doi: 10.1111/imr.12613.
9
Interleukin-18: Biological properties and role in disease pathogenesis.
Immunol Rev. 2018 Jan;281(1):138-153. doi: 10.1111/imr.12616.
10
Why the CANTOS Is a Game Changer in Cardiovascular Medicine.
J Cardiovasc Pharmacol. 2017 Dec;70(6):353-355. doi: 10.1097/FJC.0000000000000546.
Zotero 插件